Department of Ophthalmology, ASL BA-Ospedale della Murgia "Fabio Perinei," Altamura, Italy.
Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy; and.
Retin Cases Brief Rep. 2020 Spring;14(2):141-145. doi: 10.1097/ICB.0000000000000643.
To study the efficacy of a single intravitreal injection of air as a valuable alternative to current treatment options (conservative, pharmacological, and surgical) in patients with symptomatic, focal vitreomacular traction.
Interventional, nonrandomized clinical study including a consecutive series of patients who underwent a single injection of 0.3 mL of air for vitreomacular traction. Each patient underwent best-corrected visual acuity, and spectral domain optical coherence tomography before and after the procedure. Mean maximal horizontal vitreomacular adhesion and a maximal foveal thickness were measured manually.
Four eyes of four patients, all males, were included in the study. Mean age was 71 ± 6.7 years; mean best-corrected visual acuity was 0.3 ± 0.08 logarithm of the minimum angle of resolution (logMAR) (20/40 Snellen equivalent). One month following treatment, complete resolution of vitreomacular traction was achieved in 100% of eyes. Mean visual acuity postinjection was 0.18 ± 0.09 logMAR (20/32 Snellen equivalent) (Student's t test for repeated measures P = 0.03). No correlation has been found between horizontal vitreomacular adhesion and best-corrected visual acuity or maximal foveal thickness and best-corrected visual acuity (P = 0.7 and P = 0.9, respectively).
Intravitreal injection of air could offer a minimally invasive, low-cost alternative treatment in patients with symptomatic, persisting vitreomacular traction. Additional studies on a larger number of patients are required.
研究在有症状的、持续性玻璃体黄斑牵引的患者中,单次玻璃体内注射空气作为当前治疗选择(保守、药物和手术)的一种有价值的替代方法的疗效。
本研究为一项干预性、非随机的临床研究,纳入了连续系列接受单次 0.3ml 空气注射以治疗玻璃体黄斑牵引的患者。每位患者在治疗前后均接受最佳矫正视力和频域光学相干断层扫描检查。手动测量最大水平玻璃体黄斑粘连和最大中心凹厚度。
本研究纳入了 4 名男性患者的 4 只眼。平均年龄为 71 ± 6.7 岁;平均最佳矫正视力为 0.3 ± 0.08 最小角分辨率对数(logMAR)(20/40 斯耐伦等效视力)。治疗后 1 个月,所有眼的玻璃体黄斑牵引均完全缓解。注射后平均视力为 0.18 ± 0.09 logMAR(20/32 斯耐伦等效视力)(重复测量学生 t 检验 P = 0.03)。水平玻璃体黄斑粘连与最佳矫正视力或最大中心凹厚度与最佳矫正视力之间未发现相关性(P = 0.7 和 P = 0.9,分别)。
玻璃体内注射空气可能为有症状的、持续性玻璃体黄斑牵引的患者提供一种微创、低成本的替代治疗方法。需要对更多患者进行更大规模的研究。